Many companies face the reality of rapidly depleting funds, forcing difficult decisions about pipeline programs, including the pace of development, meeting the regulatory requirements to ensure a successful IND or NDA, and recruiting and maintaining the talent required to successfully execute on the requirements. In 2023 and into 2024, many small and midsized life sciences companies had to make the difficult decision to lay-off key talent and shelve or pause promising programs that with proper funding would have been great candidates for the clinic. As an alternative, it has become crucial for companies to find the quality talent at the right time and at the right price.
|